Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0787
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2613
    -0.0009 (-0.07%)
     
  • USD/JPY

    151.3070
    -0.0650 (-0.04%)
     
  • Bitcoin USD

    70,145.69
    -663.97 (-0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline

Arena Pharmaceuticals’ ARNA shares have surged 46.8% in the past six months against the industry’s 24.8% decline.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

This rise is primarily attributable to a definitive agreement entered by Arena last month with Pfizer PFE, wherein the latter will acquire the former in an all-cash transaction for $100 per share or a total equity value of approximately $6.7 billion.

Currently, Arena has no marketable products in its portfolio. The company’s late-stage candidate, etrasimod, is being evaluated in two pivotal phase III studies evaluating etrasimod for treating ulcerative colitis (“UC”). Top-line data from both the studies are expected in first-quarter 2022. The successful completion of the study will lead to the potential approval of the candidate as a treatment for UC.

Apart from UC, etrasimod is also being studied across multiple gastroenterology and dermatology indications. While the candidate is expected to soon enter into a phase III program for atopic dermatitis, it is being evaluated in separate mid-stage studies for eosinophilic esophagitis, Crohn’s disease and alopecia areata indications.

Other than etrasimod, Arena has two other mid-stage candidates — APD418 and temanogrel — in its pipeline that are being developed as treatments for cardiovascular disorders in separate phase II studies. Temanogrel is also being evaluated in a phase II study in Raynaud’s phenomenon secondary to systemic sclerosis.

Last July, Arena entered into a strategic collaboration with Aristea Therapeutics to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by the former for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. The company has an exclusive option to acquire Aristea upon completion of the phase IIb study for RIST4721 in PPP indication.

The acquisition deal between Pfizer and Arena is a win-win for both the companies. Since Arena has no marketable products in its portfolio, it lacks a steady stream of revenues. The acquisition by a big pharma giant like Pfizer, which is sitting on high reserves of cash, would allow the company to advance the development of its pipeline. Once the pipeline candidates are approved for marketing, Arena will have access to Pfizer’s larger and well-established commercial supply chain and network distribution.

In Pfizer’s case, the addition of a promising late-stage candidate like etrasimod will help it save the time required for developing a candidate from scratch. The COVID-19 vaccine sales have significantly boosted Pfizer’s revenues and cash resources. Pfizer is also looking to utilize cash resources to expand its pipeline. Over the next few years, several products in Pfizer’s portfolio will face patent expiration.

Even though Pfizer already has drugs approved for treating indications, for which Arena is evaluating etrasimod, there is a difference in the mechanism of action.

Both Arena and Pfizer did not provide any timeline for closing this deal, which is subject to customary closing conditions, including approval from Arena’s shareholders and regulatory authorities.

Arena Pharmaceuticals, Inc. Price

Arena Pharmaceuticals, Inc. Price
Arena Pharmaceuticals, Inc. Price

Arena Pharmaceuticals, Inc. price | Arena Pharmaceuticals, Inc. Quote

Zacks Rank & Other Stocks to Consider

Arena currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the same sector include BioNTech BNTX and Vir Biotechnology VIR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

BioNTech’s earnings per share estimates for 2022 have increased from $30.97 to $32.52 in the past 30 days. Shares of BioNTech have risen 92.9% in the past year.

Earnings of BioNTech beat estimates in all the last four quarters, delivering a surprise of 132.4%, on average.

Vir Biotechnology’s bottom-line estimates for 2022 have been revised from a loss of $0.01 per share to earnings of $6.82 in the past 30 days.

Earnings of Vir Biotechnology beat estimates in two of the last four quarters while missing on the other two occasions. Resultantly, VIR has an average earnings surprise of 13%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Arena Pharmaceuticals, Inc. (ARNA) : Free Stock Analysis Report

Vir Biotechnology, Inc. (VIR) : Free Stock Analysis Report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement